Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

37
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
37
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.5K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.5K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

38
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
38
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

37
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
37
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

32
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
32
Hepatic Portal System01:21

Hepatic Portal System

3.1K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reframing Evidence-Based Medicine Education: A Shift Toward Practical Practice.

Journal of evidence-based medicine·2026
Same author

Do Improving Hepatic Biomarkers Predict Spontaneous Stone Passage? A Retrospective Analysis of ERCP Yield in Suspected Choledocholithiasis.

Digestive diseases and sciences·2026
Same author

Severe hemobilia secondary to a gastroduodenal artery pseudoaneurysm in a patient with pancreatic cancer and a biliary metal stent.

Revista espanola de enfermedades digestivas·2026
Same author

Perioperative management of patients taking sodium-glucose cotransporter 2 inhibitors: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement.

British journal of anaesthesia·2026
Same author

Perioperative Anemia and Coagulopathy Management in Pediatric Patients with Medical Complexity.

Pediatric clinics of North America·2026
Same author

Distill to the Core: Perioperative Considerations for Children with Medical Complexity.

Pediatric clinics of North America·2026
Same journal

Lessons from extended induction and practical evidence for improving tofacitinib therapy in ulcerative colitis.

World journal of gastroenterology·2026
Same journal

Small animal <i>ex vivo</i> machine perfusion of the liver: A comprehensive literature review.

World journal of gastroenterology·2026
Same journal

Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics <i>vs</i> biosimilars.

World journal of gastroenterology·2026
Same journal

Diagnosis and management of metabolic dysfunction-associated steatohepatitis in patients with chronic hepatitis B infection.

World journal of gastroenterology·2026
Same journal

Simultaneous treatment of concomitant achalasia coexisting with epiphrenic diverticulum: The practice of submucosal tunneling technique.

World journal of gastroenterology·2026
Same journal

Lianhe Xiaozhi ointment ameliorates metabolic dysfunction-associated steatotic liver disease <i>via</i> peroxisome proliferator-activated receptor alpha pathway activation.

World journal of gastroenterology·2026
See all related articles

Related Experiment Video

Updated: Oct 26, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.0K

Liver dysfunction and SARS-CoV-2 infection.

Abraham Edgar Gracia-Ramos1, Joel Omar Jaquez-Quintana2, Raúl Contreras-Omaña3

  • 1Department of Internal Medicine, General Hospital, National Medical Center "La Raza", Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico. dr.gracia.dmm@gmail.com.

World Journal of Gastroenterology
|July 30, 2021
PubMed
Summary
This summary is machine-generated.

Coronavirus disease 2019 (COVID-19) can cause liver injury in about 20% of patients, impacting disease severity. Patients with pre-existing liver conditions face higher risks, necessitating careful management.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Internal Medicine

Background:

Keywords:
COVID-19CirrhosisCoronavirusLiverLiver diseasesLiver failureLiver injurySARS-CoV-2

More Related Videos

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.4K

Related Experiment Videos

Last Updated: Oct 26, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.0K
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.4K
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily targets the respiratory system but also causes multi-organ damage.
  • Liver injury is a significant extrapulmonary manifestation of COVID-19, affecting approximately 20% of patients.
  • Abnormal liver tests in COVID-19 patients correlate with increased disease severity and mortality.